The Bioproduct Research and Development team at Eli Lilly is leveraging automation to improve the quality and efficiency of biotherapeutic production and delivery. We have developed and implemented a variety of automation solutions, including a process for automating the filling and labeling of reference standard vials, a fully customized cell sorting platform for autonomous cell line development, and a system for inoculating agar plates with bacterial or fungal cultures in a spiral pattern for safety and efficacy testing, among others. These solutions not only reduce manual labor and human error but also increase the speed and accuracy of bioproduct development, thereby supporting downstream clinical trials and commercialization efforts.